SineuGene Therapeutics Reports the US FDA’s IND Clearance of SNUG01 for Amyotrophic Lateral Sclerosis
Shots:
- The US FDA has granted IND clearance to SNUG01 for ALS
- SNUG01 will be evaluated in a P-I/IIa dose-escalation & expansion trial to assess its safety, tolerability, & preliminary efficacy in ALS adults; SineuGene to partner with academics & institutions to lead clinical development of SNUG01
- SNUG01, a TRIM72-targeted gene therapy, counteracts ALS through ROS scavenging, mitochondrial homeostasis, stress granule regulation, neuroinflammation inhibition, & membrane repair as shown in preclinical models while in an IIT trial, SNUG01 demonstrated safety, tolerability, & early efficacy
Ref: Prnewswire | Image: SineuGene
Related News:- GSK Reports the EMA’s Acceptance of Nucala (Mepolizumab) as an Add-on Treatment for COPD
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
